Mineralys Therapeutics announced on September 4, 2025, the closing of its upsized underwritten public offering of 11,274,509 shares of common stock. This included the full exercise of the underwriters’ option to purchase an additional 1,470,588 shares.
The aggregate gross proceeds to Mineralys from the offering totaled approximately $287.5 million. All of the securities sold in the offering were sold by Mineralys, further bolstering its financial resources.
The net proceeds are intended to fund the clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization activities. This significant capital infusion also supports working capital and general corporate purposes, extending the company's financial runway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.